@techreport{oai:kindai.repo.nii.ac.jp:00023292,
 author = {中山, 聖子},
 month = {},
 note = {https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20K17413/, 研究成果の概要（和文）：びまん性大細胞型B細胞リンパ腫･非特異型 (DLBCL,NOS) の新たな予後予測指標として、我々は貧血や血小板減少の有無に基づく Hemoglobin-platelet index (HPI) を提唱した。Cox比例ハザードモデルによる生存時間分析にて統計学的に解析した結果、HPI score が高い症例ほど全生存期間及び無増悪生存期間が有意に短かった。さらにHPIは、既存の国際予後指標 (NCCN-IPI) と独立した予後予測指標であった。また、免疫染色でリンパ腫細胞がIL-6陽性の患者群では、陰性群よりヘモグロビン値と血小板数が有意に低かった。
研究成果の概要（英文）： We assessed the utility of a novel hemoglobin-platelet index (HPI), based on anemia and thrombocytopenia, as a prognostic predictor in diffuse large B-cell lymphoma, not otherwise specified (DLBCL,NOS).The patients with a higher HPI score had significantly worse outcomes, and the HPI was independent of the National Comprehensive Center Network-International Prognostic Index (NCCN-IPI) to predict the prognosis. In addition, the patients which tumor cells were immunohistochemically positive for interleukin-6 (IL-6) had significantly lower hemoglobin levels or platelet counts than those which tumor cells were negative for IL-6. HPI was a simple and useful prognostic predictor for DLBCL,NOS patients. Therefore, combining HPI with NCCN-IPI might be useful to predict the prognosis of the patients more accurately. Moreover, anemia and thrombocytopenia complicated in DLBCL, NOS patients might be caused by IL-6 production by
lymphoma cells themselves., 研究種目：若手研究; 研究期間：2020～2021; 課題番号：20K17413; 研究分野：悪性リンパ腫の予後予測; 科研費の分化・細目：, application/pdf},
 title = {DLBCL,NOSの血算値に基づく新規予後予測指標の確立及び血球減少の病態解明},
 year = {2021},
 yomi = {ナカヤマ, ショウコ}
}